HSA published Version 6 of the Guidance for Industry Post-Marketing Vigilance Requirements for Therapeutic Products and Cell, Tissue and Gene Therapy Products on 1 April 2026: 11 section-level revisions including spontaneous-vs-solicited adverse-event distinction, eCTD submission platform alternative, identifiable-patient examples, lack-of-efficacy criteria refresh, and clinical-safety-study-report inclusion. Singapore CTGTP regime continues 15-year long-term follow-up for gene therapy products. Operational under the Health Products Act 2007.

The Health Sciences Authority (HSA) published Version 6 of the Guidance for Industry — Post-Marketing Vigilance Requirements for Therapeutic Products and Cell, Tissue and Gene Therapy Products on 1 April 2026. The Guidance, an HSA Vigilance and Compliance Branch (VCB) document under the Health Products Act 2007 (Act 14 of 2007) and its Health Products (Therapeutic Products) Regulations 2016 and Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021, operationalises post-market pharmacovigilance and risk-management obligations for registrants, manufacturers, importers, and suppliers of registered therapeutic products and CTGTPs in Singapore. Version 6 supersedes Version 5 of 7 October 2024.

Version 6 introduces eleven section-level revisions documented in the Guidance's own Revision History. Section 4 updates serious-adverse-event submission criteria with explicit distinction between spontaneous and solicited reports; Section 4.1 adds examples defining "identifiable patient"; Section 4.4 reiterates medical-confirmation and follow-up requirements for consumer-reported events; Section 4.5 updates literature-derived adverse-event submission criteria. Sections 5.1, 7.1.2, and 7.2 add electronic Common Technical Document (eCTD) as an alternative submission platform. Section 5.3 updates lack-of-efficacy reporting criteria. Section 8 amends its introductory paragraph to include clinical safety study reports.

The pharmacovigilance regime under Version 6 spans the full product lifecycle. Companies must maintain adverse-event records; submit serious adverse events on an expedited basis using either the CIOMS I form or the HSA online reporting form; report adverse events arising in special situations including pregnancy, drug overdose, medication error, and lack of efficacy; develop Risk Management Plans (RMPs) for new drug applications type 1 (NDA-1); and implement routine and additional pharmacovigilance and risk-minimisation activities throughout the post-approval period. The Singapore-Specific Annex (SSA) — a four-page interactive PDF form effective 1 April 2024 — must accompany every NDA-1 dossier.

The RegLegBrief Specialist Panel considered Version 6 alongside the HSA Singapore-Specific Annex form, the HSA Risk Management Plans Overview, the HSA Guidance Documents indices for therapeutic products and CTGTP, and the World Health Organization-published Health Sciences Authority of Singapore Pharmacovigilance Journey institutional narrative. Together these documents establish that the HSA Vigilance and Compliance Branch operates a mature post-market surveillance regime — Singapore's adverse-event reporting was ranked first globally by the WHO in 2011 and has maintained a top-three position since — within which Version 6 is the latest in a series of incremental technical refinements rather than a structural reset.

Read against the comparable jurisdiction cohort, the Specialist Panel finds Version 6 directly aligned with international pharmacovigilance harmonisation. The ICH E2D Guideline on Post-Approval Safety Data Management (Step 4 adoption 12 November 2003; the ICH E2D(R1) revision takes effect in the European Union from 18 March 2026, contemporaneous with Version 6) anchors the adverse-event definitions, individual-case-safety-report content, and expedited-reporting timelines that Version 6 Section 4 implements. The ICH E2E Guideline on Pharmacovigilance Planning (Step 4 adoption 18 November 2004) provides the forward-looking pharmacovigilance-planning framework operationalised in Version 6 Section 6 Risk Management Plans.

The European Union's Directive 2010/84/EU amending Directive 2001/83/EC and the companion Regulation (EU) No 1235/2010 amending Regulation (EC) No 726/2004 establish the EU pharmacovigilance legislation that the European Medicines Agency operationalises through the Good Pharmacovigilance Practices (GVP) modules I to XVI; the modules cover pharmacovigilance system master files, audits, risk-management systems, and adverse-reaction collection in a sixteen-module framework that informs HSA's reference-RMP architecture under Version 6 sections 7.1.2 and 7.1.3. The United States Food and Drug Administration's Risk Evaluation and Mitigation Strategies regime under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355-1) — including Elements to Assure Safe Use, communication plans, and medication guides — provides the parallel risk-minimisation reference for V6's catalogue. The complete document set is listed in the document panel below.

Version 6 sits in a contiguous regulatory cluster with two sibling RegLegBrief CITED signals. The Specialist Panel's analysis at RegLegBrief citation RLB-SG-2026-00060 covers the AI in Healthcare Guidelines Version 2.0 jointly issued by MOH and HSA on 10 March 2026, addressing post-deployment monitoring of AI-enabled medical devices that may themselves be CTGTPs subject to Version 6. The Specialist Panel's analysis at RegLegBrief citation RLB-SG-2026-00063 covers the HSA-Japan Ministry of Health, Labour and Welfare Memorandum of Cooperation of 20 April 2026, which establishes bilateral reliance for medicines, cell, tissue and gene therapy products, and medical devices across the full lifecycle including post-market oversight.

The professional categories materially affected fall into four named groups. Pharmaceutical and CTGTP company representatives — registrants, manufacturers, importers, and suppliers operating under licences issued pursuant to the Health Products Act 2007 — bear primary responsibility for adverse-event reporting and RMP submission. Local pharmacovigilance personnel and qualified persons for pharmacovigilance employed by registrants must implement the Section 2 point-of-contact requirements. Pharmacists registered with the Singapore Pharmacy Council under the Pharmacists Registration Act 2007 (Act 26 of 2007) employed in industry pharmacovigilance and regulatory-affairs functions must apply the updated Section 4.4 medical-confirmation criteria. Medical practitioners registered with the Singapore Medical Council under the Medical Registration Act 1997 in clinical pharmacovigilance roles must observe the Section 5 special-situations reporting framework.

The operational delta between Version 5 and Version 6 is incremental rather than structural. Companies operating compliant pharmacovigilance systems under Version 5 should reconcile their standard operating procedures against the Section 4 spontaneous-vs-solicited distinction, the Section 4.1 identifiable-patient examples, the Section 4.5 literature-monitoring criteria, the eCTD submission alternative, and the Section 5.3 lack-of-efficacy criteria. The CTGTP-specific long-term follow-up obligation — extending up to fifteen years for gene therapy products with delayed adverse-event risks such as insertional mutagenesis or secondary malignancies — continues unchanged from earlier Versions and remains a defining feature of the Singapore CTGTP regime.

Version 6 takes effect from its publication on 1 April 2026 with no transitional grace period. Companies should align internal pharmacovigilance procedures and RMP-submission practices against the eleven Revision History items before the next adverse-event reporting cycle. Outstanding RMPs in development for new drug applications type 1 should incorporate the Section 7.1.1 revised hyperlink to the Singapore-Specific Annex and the Section 8.5 eCTD alternative where applicable. This regulatory development is preserved and cited by RegLegBrief at reglegbrief.com/cite/RLB-SG-2026-00064.